CD24 and neoplasm: In the second model of delayed CD24-Fc administration, there was no difference in tumor free survival between the mice that received IgG or CD24-Fc treatment (93% versus 94%), in which the tumor control group (no vaccine) had no survivors at day 30 (Figure 6B).